On October 2, EVEREST MED fell 5.04% in regular trading, trading at HK$28.28/share, with turnover of HK$2.4045 million. The stock opened sharply lower after surging 7.72% in the prior session, as the broader biotechnology sector gave back gains.

The previous trading day saw a broad rally across innovative drug and mRNA concept stocks, fueled by Moderna's mRNA neoantigen therapy data presented at the ESMO conference. EVEREST MED was among the beneficiaries, with market attention on its proprietary mRNA tumor vaccine pipeline EVM16, which the company plans to advance into a Phase Ib investigator-initiated trial in Q4. Today's retreat reflects profit-taking across the sector following that catalyst-driven spike.

Within the Biotechnology sector, stocks declined broadly. Among peers, BEONE MEDICINES fell 6.74%, INNOVENT BIO fell 4.84%, SKB BIO fell 3.45%, AKESO fell 2.30%, and HENLIUS fell 0.85%, indicating sector-wide selling pressure rather than company-specific weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)